HER2-negative metastatic breast cancer
Lynparza Approved to Treat BRCA-Mutated Metastatic Breast Cancer
The FDA expanded the approved use of olaparib (Lynparza, AstraZeneca) to include the treatment of patients with ...
JANUARY 14, 2018
Olaparib Provides PFS Benefit in Pts With HER2-Negative Breast Cancer
Chicago—Relative to single-agent chemotherapies, olaparib delays time to both first and second progression in ...
JULY 12, 2017
VEGF Biomarker Not Predictive of Bevacizumab + Paclitaxel Efficacy
Adding bevacizumab to paclitaxel significantly improved PFS over placebo in patients with HER2-negative mBC, but an ...
FEBRUARY 13, 2017
Load more